Novartis Aktie
WKN: 907122 / ISIN: US66987V1098
17.07.2025 07:35:35
|
Novartis Q2 Profit Rises,lifts FY Core Operating Profit Growth View; Initiates $10 Bln Share Buyback
(RTTNews) - Swiss drug major Novartis AG (NVS) reported that its net income attributable to shareholders for the second quarter rose to $4.041 billion or $2.06 per share from last year's $3.246 billion or $1.59 per share, mainly driven by higher operating income, partly offset by higher net financial expense.
The company is initiating a share buyback program of up to US$10 billion, with completion expected by the end of 2027.
Looking ahead, the company now expects core operating income for fiscal year 2025 to grow in the low teens compared to the prior year, revising its earlier outlook of low double-digit growth. Annual sales are still expected to grow high single digit from the prior year. The outlook reflects growth compared to the prior year on a constant currency basis.
Novartis's core net income attributable to shareholders for the quarter was $4.709 billion or $2.42 per basic share up from $4.008 billion or $1.97 per basic share in the previous year.
Net sales to third parties for the second quarter increased to $14.054 billion from $12.512 billion last year.
For more earnings news, earnings calendar, and earnings for stocks, visit rttnews.com.

Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
Nachrichten zu Novartis AG (Spons. ADRS)mehr Nachrichten
09.09.25 |
Novartis-Aktie verliert: Konzern will Tourmaline Bio für Milliardenbetrag kaufen (Dow Jones) | |
02.09.25 |
Novartis sichert sich Lizenzrechte für Parkinson-Behandlung von Arrowhead - Aktien uneins (Dow Jones) | |
12.08.25 |
Novartis-Aktie gefragt: Klinischer Studienerfolg mit Ianalumab (Dow Jones) | |
11.08.25 |
Novartis-Aktie höher: Ianalumab punktet bei Autoimmun-Erkrankung (Dow Jones) | |
16.07.25 |
Ausblick: Novartis öffnet die Bücher zum abgelaufenen Quartal (finanzen.net) | |
03.07.25 |
Novartis-Aktie tiefer: Cosentyx-Studie liefert nicht die erwarteten Ergebnisse (Dow Jones) | |
02.07.25 |
Erste Schätzungen: Novartis stellt Zahlen zum jüngsten Quartal vor (finanzen.net) | |
29.04.25 |
Novartis-Aktie im Plus: Prognose nach starkem Start ins Jahr erhöht (Dow Jones) |
Analysen zu Novartis AG (Spons. ADRS)mehr Analysen
Aktien in diesem Artikel
Novartis AG (Spons. ADRS) | 104,00 | 0,48% |
|